Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…Abstract Number: L10 • ACR Convergence 2021
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…Abstract Number: 166 • 2020 Pediatric Rheumatology Symposium
Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in pathogen defense. Dysregulated…Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…Abstract Number: 36 • 2019 ACR/ARP Annual Meeting
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…Abstract Number: 117 • 2019 ACR/ARP Annual Meeting
The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of synovium, which causes progressive joint destruction and reduction in quality of life.…Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…Abstract Number: 315 • 2019 ACR/ARP Annual Meeting
Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire
Background/Purpose: The use of biologics has transformed the treatment paradigm for RA; however, reactivation of Mycobacterium Tuberculosis is still a concern. Frequent TB screenings without…Abstract Number: 454 • 2019 ACR/ARP Annual Meeting
Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study
Background/Purpose: Determining the prognosis of rheumatoid arthritis (RA) could guide more precise treatment selection, optimizing outcomes while minimizing unnecessary therapeutic exposures. It is important that…Abstract Number: 488 • 2019 ACR/ARP Annual Meeting
Citrullinated Antigens with Multiple Citruline Similar Motif Could Be Used for RA Diagnosis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic joint inflammation that ultimately leads to joint destruction. Diagnosis of RA is important…Abstract Number: 535 • 2019 ACR/ARP Annual Meeting
Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA
Background/Purpose: Treatment of pain remains a priority for patients (pts) with RA. Otilimab (GSK3196165) is a human mAb that inhibits GM-CSF, a key driver in…Abstract Number: 840 • 2019 ACR/ARP Annual Meeting
Trajectory of Multimorbidity in Rheumatoid Arthritis in a U.S. Commercial Insurance Claims Database from 2006-2015
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, predisposes individuals to disability and premature mortality. RA is well known to be associated with select chronic…
- 1
- 2
- 3
- …
- 56
- Next Page »